Cargando…
Role of Glucagon‐Like Peptide‐1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity
Obesity remains a major public health problem, affecting almost half of adults in the United States. Increased risk of cardiovascular disease (CVD) and CVD mortality are major obesity‐related complications, and management guidelines now recommend weight loss as a key strategy for the primary prevent...
Autores principales: | Michos, Erin D., Lopez‐Jimenez, Francisco, Gulati, Martha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381974/ https://www.ncbi.nlm.nih.gov/pubmed/37278394 http://dx.doi.org/10.1161/JAHA.122.029282 |
Ejemplares similares
-
Evolving Management of Low‐Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum
por: Wilkinson, Michael J., et al.
Publicado: (2023) -
Natriuretic Peptides in the Regulation of Cardiovascular Physiology and Metabolic Events
por: Kerkelä, Risto, et al.
Publicado: (2015) -
Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention
por: Kohli, Payal, et al.
Publicado: (2014) -
Weight loss with glucagon‐like peptide‐1 receptor agonists in Bardet‐Biedl syndrome
por: Ganawa, Shawg, et al.
Publicado: (2022) -
Targeting Inflammation to Reduce Atherosclerotic Cardiovascular Risk in People With HIV Infection
por: Titanji, Boghuma, et al.
Publicado: (2020)